60 Degrees Pharmaceuticals, Inc. Is a specialty pharmaceutical company focused on the development and commercialization of new medicines to treat and prevent infectious diseases. The company leverages biological science and applied research to create novel therapies for vector-borne, fungal, and viral illnesses. This perform represents a growing trend in targeted pharmaceutical development, aiming to address specific disease vectors with precision.
The company’s development pipeline currently includes programs centered around three core products: new formulations containing the ARAKODA regimen of Tafenoquine, additional Tafenoquine products, and Celgosivir. Its lead product, ARAKODA, is a prophylactic treatment for malaria indicated for patients 18 years of age and older.
60 Degrees Pharmaceuticals is also actively pursuing potential licensing opportunities related to a Lyme disease product and a combination therapy featuring Tafenoquine for P. Vivax malaria, according to company statements. Founded in 2010, the company is headquartered in Washington, D.C. And trades on the NASDAQ under the ticker symbol SXTP. As of February 12, 2026, the company’s stock was trading at $3.950.
Beyond malaria, 60 Degrees Pharmaceuticals is conducting clinical trials for Tafenoquine in Phase IIb for COVID-19 indications and Phase IIA trials for babesiosis, fungal pneumonias, and candidiasis. The company also holds a patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of Tafenoquine for the treatment and prevention of babesiosis.
